Trial Profile
A Pilot Pre-Surgical Study Evaluating Anti-PD-L1 Antibody (Durvalumab) Plus Anti-CTLA-4 (Tremelimumab) in Patients With Muscle-Invasive, High-Risk Urothelial Carcinoma Who Are Ineligible for Cisplatin-Based Neoadjuvant Chemotherapy
Status:
Active, no longer recruiting
Phase of Trial:
Phase 0
Latest Information Update: 25 Sep 2023
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary) ; Tremelimumab (Primary)
- Indications Bladder cancer; Carcinoma; Renal cancer; Squamous cell cancer; Ureteral neoplasms; Urethral cancer; Urogenital cancer
- Focus Adverse reactions
- 18 Sep 2023 Planned End Date changed from 31 Mar 2023 to 31 Dec 2024.
- 18 Sep 2023 Planned primary completion date changed from 31 Mar 2023 to 31 Dec 2024.
- 29 Jun 2022 Planned End Date changed from 31 Mar 2022 to 31 Mar 2023.